Our History
Since our founding, OmniScience has partnered with over 50 life sciences teams, applying advanced AI and machine learning to hundreds of clinical trial datasets to support precision diagnostics, biomarker analytics, clinical trial analytics, clinical decision support, and market intelligence. Over the past five years, we’ve evolved from bespoke AI development to productizing our innovations, culminating in our flagship SaaS platform: Vivo.
A decade ahead
Before large language models (LLMs) entered the mainstream, we were already applying natural language processing (NLP) to the hardest problems in biomedical data—unifying fragmented datasets, synthesizing unstructured scientific content, and delivering language-driven decision support tools.
Our early NLP work laid the foundation for the genAI era. We built production-ready systems to extract gene-disease-drug relationships, identify digital & omics-based biomarkers, and unify biomedical literature to support drug discovery. These weren’t prototypes—they were deployed tools, trusted by biopharma teams tackling complex data challenges.
From analytics to actionable insights
With the advent of LLMs, we accelerated our innovation. By tuning language models with biomedical vocabularies and ontologies, we created domain-specific solutions that are interpretable, robust, and impactful.
These capabilities are deeply integrated and grounded in scientific context—enabling better, faster decisions across clinical operations and strategy.
For more details about how we’re applying LLMs and genAI in our products, see our genAI whitepaper →
